Abstract: The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of Pralsetinib and of Pralsetinib salts and co-crystals, in embodiments crystalline polymorphs of Pralsetinib, Pralsetinib salts and co-crystals processes for preparation thereof, and pharmaceutical compositions thereof. The present disclosure encompasses solid state forms of Pralsetinib and of Pralsetinib salts and co-crystals, in embodiments crystalline polymorphs of Pralsetinib, Pralsetinib salts and co-crystals processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of Trilaciclib and of Trilaciclib salts, in embodiments crystalline polymorphs of Trilaciclib and of Trilaciclib salts, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

Abstract: The invention relates to a vial adaptor. The vial adaptor comprises a syringe connection port. The syringe connection port is configured to be connected to a syringe. The vial adaptor further comprises a vial connection port. The vial connection port comprises a skirt and a spike. The spike has a lumen forming a fluid channel. The vial adaptor further comprises a conduit configured to provide fluid flow between the syringe connection port and the vial connection port. The vial adaptor further comprises a valve for selectively blocking and allowing fluid flow between the syringe and the conduit through the syringe connection port when the syringe is connected to the syringe connection port. This constitutes an improved solution for connecting a syringe and a vial.

Abstract: The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: Disclosed are solid state forms of lumateperone ditosylate, uses thereof, and pharmaceutical compositions thereof.

Abstract: Disclosed crystalline Siponimod fumaric acid, solid state forms (polymorphs) thereof, processes for preparation thereof and pharmaceutical compositions thereof.

Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

Abstract: A method of adapting an auto injector configured to actuate a prefilled syringe, the auto injector having a biasing member having a spring constant, the prefilled syringe being filled with a volume of therapeutic fluid, the prefilled syringe including a barrel, stopper, and a needle, the stopper having a path of travel, the biasing member arranged to move the stopper along the path of travel. An auto injector having an injection spring adapted to an aged prefilled syringe.

Abstract: The present disclosure relates to solid state forms of Pemafibrate processes for preparation thereof and pharmaceutical compositions thereof.

Abstract: Disclosed are solid state forms of lumateperone ditosylate, uses thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure provides solid state forms of Relugolix, crystalline forms of Relugolix, pharmaceutical compositions thereof, and pharmaceutical formulations thereof. Methods for producing these forms of Relugolix, pharmaceutical compositions, and pharmaceutical formulations are also provided.

Abstract: The present disclosure encompasses crystalline polymorphs of Ponesimod, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure relates to solid state forms of Pemafibrate processes for preparation thereof and pharmaceutical compositions thereof.

Abstract: A method of adapting an auto injector configured to actuate a prefilled syringe, the auto injector having a biasing member having a spring constant, the prefilled syringe being filled with a volume of therapeutic fluid, the prefilled syringe including a barrel, stopper, and a needle, the stopper having a path of travel, the biasing member arranged to move the stopper along the path of travel. An auto injector having an injection spring adapted to an aged prefilled syringe.

Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.

Abstract: Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

Abstract: Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.